HK1218071A1 - 在預防和治療眼滲透性過高症中的抑制 - Google Patents
在預防和治療眼滲透性過高症中的抑制Info
- Publication number
- HK1218071A1 HK1218071A1 HK16106068.6A HK16106068A HK1218071A1 HK 1218071 A1 HK1218071 A1 HK 1218071A1 HK 16106068 A HK16106068 A HK 16106068A HK 1218071 A1 HK1218071 A1 HK 1218071A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- sema3a
- hyperpermeability
- ocular
- inhibition
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361767419P | 2013-02-21 | 2013-02-21 | |
PCT/CA2014/050119 WO2014127479A1 (en) | 2013-02-21 | 2014-02-21 | Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1218071A1 true HK1218071A1 (zh) | 2017-02-03 |
Family
ID=51390449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16106068.6A HK1218071A1 (zh) | 2013-02-21 | 2016-05-27 | 在預防和治療眼滲透性過高症中的抑制 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9822367B2 (zh) |
EP (1) | EP2958580A4 (zh) |
JP (1) | JP6437462B2 (zh) |
AU (1) | AU2014221144B2 (zh) |
CA (1) | CA2901946C (zh) |
HK (1) | HK1218071A1 (zh) |
WO (1) | WO2014127479A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6437462B2 (ja) | 2013-02-21 | 2018-12-12 | アールエスイーエム・リミテッド・パートナーシップ | 眼内透過性亢進の予防及び治療におけるsema3aの阻害 |
LT3189074T (lt) | 2014-09-05 | 2021-06-10 | Rsem, Limited Partnership | Kompozicijos ir būdai skirti uždegimo gydymui ir prevencijai |
AU2016346595B2 (en) * | 2015-10-27 | 2019-11-14 | Pangen Biotech Inc. | Antibody to be cross-linked to human and mouse Sema3A, and use thereof |
US10604572B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse Sema3A and use thereof |
US10640777B2 (en) | 2015-10-27 | 2020-05-05 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
US10604571B2 (en) | 2015-10-27 | 2020-03-31 | Samsung Life Public Welfare Foundation | Antibody to human and mouse SEMA3A and use thereof |
US20200056186A1 (en) * | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
WO2019044758A1 (ja) | 2017-08-29 | 2019-03-07 | 東レ株式会社 | ポリプロピレンフィルム、金属膜積層フィルムおよびフィルムコンデンサ |
BR112021019854A2 (pt) * | 2019-05-09 | 2022-02-15 | Boehringer Ingelheim Int | Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares |
EP3990488A4 (en) * | 2019-06-27 | 2023-09-13 | Ramot at Tel-Aviv University Ltd. | SEMAPHORIN 3A ANTIBODIES AND THEIR USES |
TW202126685A (zh) * | 2019-09-24 | 2021-07-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 |
US20220127344A1 (en) * | 2020-10-23 | 2022-04-28 | Boehringer Ingelheim International Gmbh | Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999029858A1 (en) * | 1997-12-09 | 1999-06-17 | Children's Medical Center Corporation | Soluble inhibitors of vascular endothelial growth factor and use thereof |
WO2010027743A1 (en) | 2008-08-25 | 2010-03-11 | Alpha Synergy Development, Inc. | Pharmaceutical compositions and methods for the treatment of dry eye |
WO2011066284A1 (en) * | 2009-11-25 | 2011-06-03 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of immune disorders |
ES2728854T3 (es) | 2013-02-06 | 2019-10-29 | Univ Yokohama City | Anticuerpo anti-semaforina 3A y tratamiento de enfermedad de Alzheimer y enfermedades inmunitarias inflamatorias usando el mismo |
JP6437462B2 (ja) | 2013-02-21 | 2018-12-12 | アールエスイーエム・リミテッド・パートナーシップ | 眼内透過性亢進の予防及び治療におけるsema3aの阻害 |
-
2014
- 2014-02-21 JP JP2015558315A patent/JP6437462B2/ja active Active
- 2014-02-21 EP EP14754943.0A patent/EP2958580A4/en active Pending
- 2014-02-21 AU AU2014221144A patent/AU2014221144B2/en active Active
- 2014-02-21 CA CA2901946A patent/CA2901946C/en active Active
- 2014-02-21 WO PCT/CA2014/050119 patent/WO2014127479A1/en active Application Filing
- 2014-02-21 US US14/769,255 patent/US9822367B2/en active Active
-
2016
- 2016-05-27 HK HK16106068.6A patent/HK1218071A1/zh unknown
-
2017
- 2017-10-16 US US15/784,499 patent/US10612028B2/en active Active
-
2020
- 2020-03-04 US US16/808,611 patent/US11268097B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US10612028B2 (en) | 2020-04-07 |
US20180030455A1 (en) | 2018-02-01 |
WO2014127479A1 (en) | 2014-08-28 |
US20160002641A1 (en) | 2016-01-07 |
AU2014221144A1 (en) | 2015-09-03 |
EP2958580A4 (en) | 2016-09-21 |
JP2016516003A (ja) | 2016-06-02 |
CA2901946A1 (en) | 2014-08-28 |
EP2958580A1 (en) | 2015-12-30 |
US20200208159A1 (en) | 2020-07-02 |
US11268097B2 (en) | 2022-03-08 |
AU2014221144B2 (en) | 2018-03-22 |
JP6437462B2 (ja) | 2018-12-12 |
CA2901946C (en) | 2023-01-17 |
US9822367B2 (en) | 2017-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1218071A1 (zh) | 在預防和治療眼滲透性過高症中的抑制 | |
HK1225654A1 (zh) | 用於治療老花眼的組合物及方法 | |
HK1216251A1 (zh) | 吡唑並吡咯烷衍生物及其治病作用 | |
PL3004108T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu jako inhibitory BET oraz ich zastosowanie w leczeniu chorób | |
PL3004112T3 (pl) | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby | |
PL2854910T3 (pl) | Poziomy ceramidu w leczeniu i zapobieganiu infekcjom | |
GB201515986D0 (en) | Use of cannabinoids in the treatment of mental disorders | |
EP2969001A4 (en) | USE OF LEVOCETIRIZIN AND MONTELUKAST IN THE TREATMENT OF ANAPHYLAXIS | |
PL2893019T3 (pl) | siRNA i jego zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania chorobom oczu | |
IL242355B (en) | Cannabidiol for the prevention and treatment of graft-versus-host disease | |
EP3065548A4 (en) | Fibrosis inhibiting compounds and methods of use thereof in the prevention or treatment of fibrosing diseases | |
PT3049085T (pt) | Inibidores de sgk1 no tratamento da síndrome do qt longo | |
PL3021858T3 (pl) | Szczep cu1 do leczenia i/lub profilaktyki przewlekłych zapalnych chorób reumatycznych | |
PL2862576T3 (pl) | Drobnoustroje i zawierające je kompozycje do stosowania do leczenia lub profilaktyki zapalenia sutka | |
HK1220396A1 (zh) | 痤瘡的治療和預防 | |
SG2013079843A (en) | Use of tocotrienols in the treatment or prevention of ulcerative colitis | |
PL3041459T3 (pl) | Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry | |
AP2015008849A0 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
RS59723B1 (sr) | Arginin za upotrebu u lečenju i/ili prevenciji osteoartritisa | |
GB201317373D0 (en) | Treatment and prevention of cancer |